LON:STXShield Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Shield Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 101 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range 97.40Now: GBX 101▼ 99.5050-Day Range 83MA: GBX 102.38▼ 12652-Week Range 39.10Now: GBX 101▼ 202Volume19,430 shsAverage Volume48,665 shsMarket Capitalization£118.36 millionP/E Ratio28.06Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlinesOptions Chain Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingShield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 200, Shield Therapeutics has a potential upside of 98.0% from its current price of GBX 101.Amount of Analyst CoverageShield Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesShield Therapeutics has received 206 “outperform” votes. (Add your “outperform” vote.)Underperform VotesShield Therapeutics has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentShield Therapeutics has received 59.20% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote “Outperform” if you believe STX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldShield Therapeutics does not currently pay a dividend.Dividend GrowthShield Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Shield Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Shield Therapeutics is 28.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Shield Therapeutics is 28.06, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.78.Price to Book Value per Share RatioShield Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX Previous Symbol CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500Debt Debt-to-Equity Ratio0.26 Current Ratio4.79 Quick Ratio4.57Price-To-Earnings Trailing P/E Ratio28.06 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£14.00 million Price / Sales8.45 Cash FlowGBX 5.72 per share Price / Cash Flow17.64 Book ValueGBX 33.10 per share Price / Book3.05Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares117,189,000Market Cap£118.36 million Next Earnings DateN/A OptionableOptionable LSE:STX Rates by TradingView Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Shield Therapeutics (LON:STX) Frequently Asked Questions How has Shield Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Shield Therapeutics' stock was trading at GBX 121.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STX shares have decreased by 16.9% and is now trading at GBX 101. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Shield Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Shield Therapeutics. What price target have analysts set for STX? 2 equities research analysts have issued 12-month price objectives for Shield Therapeutics' stock. Their forecasts range from GBX 200 to GBX 200. On average, they expect Shield Therapeutics' share price to reach GBX 200 in the next twelve months. This suggests a possible upside of 98.0% from the stock's current price. View analysts' price targets for Shield Therapeutics. Has Shield Therapeutics been receiving favorable news coverage? News articles about STX stock have been trending very negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Shield Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutShield Therapeutics. Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO), ICC Labs (ICC), Amryt Pharma (AMYT), Benchmark (BMK), Green Organic Dutchman (TGOD), WeedMD (WMD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Supreme Cannabis (FIRE), Althea Group (AGH) and Delta 9 Cannabis (NINE). View all competitors. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the following people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)Mr. Timothy William Watts, Chief Financial Officer (Age 61)Fleur Wood, Director of Investor RelationsMs. Lucy Bailey, Gen. Counsel & Company Sec.Ms. Suzanne Wood, Group HR Director What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 101. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £118.36 million and generates £14.00 million in revenue each year. Shield Therapeutics employs 15 workers across the globe. What is Shield Therapeutics' official website? The official website for Shield Therapeutics is www.shieldtherapeutics.com. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. This page was last updated on 5/30/2020 by MarketBeat.com Staff
